Pharmstandard sales revenues rise 12% in Q1
MOSCOW. April 29 (Interfax) - Russian pharmaceuticals company Pharmstandard saw first-quarter sales revenues of 9.14 billion rubles this year, 12% up on the same three months of 2012, the company said.
Income from the sale of pharmaceutical goods increased 11% to 8.864 billion rubles.
Sales of such products made by Pharmstandard itself amounted to 5.539 billion rubles, 36.1% more than in Q1 of last year.
Sales of Rx products increased 35.1% to 1.489 billion rubles, driven mainly by Pharmstandard's acquisition in 2012 of the companies Pharmapark, Biomed Mechnikov, and Lekko. Sales of the trademarked products Combilipen,Biosulin, Azitrox, Formetine and Altevir.
Sales of OTC products grew 36.5% year-on-year to 4.05 billion rubles in Q1. Pharmapark, Biomed Mechnikov, and Lekko accounted for 7% of the increase. The product Arbidol showed sales growth of 139% to 1.027 billion rubles. Aggregate sales of codeine-free Pentalgin and Codelac provided income growth of 95% to 593 million rubles. Sales of codeine-based Pentalgin, Codelac, and Terpincodum moved into the RX segment showed a 69.3% decrease.
Sales of third-party producer (TPP) goods amounted to 3.067 billion rubles, down 18.8%. The "TPP sales decrease in Q1 2013 is directly attributed to production localization segment decline due to lack of government purchases via public auctions under 7 Nosologies Federal Program," the company said. "Commercial TPP sales reached 1.799 million rubles (70.6% growth) primarily driven by Reduksin, Tamiflu and Xylen," it said.
Medical equipment sales were up 60.7% at 280 million rubles.
